Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5869-5876

  Personeni, Nicola ^a   Fieuws, Steffen ^c   Piessevaux, Hubert ^e   De Hertogh, Gert ^b   De Schutter, Jef ^d   Biesmans, Bart ^d   De Roock, Wendy ^d   Capoen, An ^b   Debiec Rychter, Maria ^d   Laethem, Jean LucVan ^f   Peeters, Marc ^g   Humblet, Yves ^e   Van Cutsem, Eric ^a   Tejpar, Sabine ^a,b  

^a Digestive Oncology Unit   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Biostatistical Centre   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRINOTECAN; K RAS PROTEIN; TUMOR MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EVALUATION; GENE DOSAGE; GENETIC MARKER; GENETICS; MIDDLE AGED; PROGNOSIS; PROTO ONCOGENE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE DOSAGE; GENES, ERBB-1; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS;

EID: 53249123419     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0449     Document Type: Article

References (32)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
2. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
3. Jonker D, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
4. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
5. Sartore-Bianchi A, Moroni M. Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25:3238-45.
6. Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2007;19:717-23.
7. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807.
8. Wolff AC, Hammond ME, Schwartz JN; American Society of Clinical Oncology, College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
9. Miyazaki M, FuruyaT, Shiraki A, et al. The relationship of DNA ploidy to chromosomal instability in primary human colorectal cancers. Cancer Res 1999;59: 5283-5.
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8.
11. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15.
12. Lièvre A, Bachet JB, BoigeV, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
13. Lenz HJ, Van Cutsem E. Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21.
14. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. Proc Am Soc Clin Oncol 2007;25:4037,
15. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
16. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-18.
17. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901.
18. Nathanson OR, Culliford AT IV, Shia J, et al. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003;105:796-802.
19. Harrell FE. Regression modeling strategies. New York: Springer; 2001.
20. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904.
21. Al-Kuraya K, Novotny H, Bavi P, et al. HER2, TOP2A, CCIMD1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007;60:768-72.
22. Cunningham MP, Thomas H, Fan Z, Modjtahedi H. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 2006;66:7708-15.
23. Gross ME, Zorbas MA, Danels YJ, et al. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 1991;51: 1452-9.
24. Wu X, Fan Z, Masui H, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin lnvest1995;9:1897-905.
25. ltaliano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR- inhibitors. Ann Oncol 2006;17:981-5.
26. Bozzetti C, Tiseo M, Lagrasta C, et al. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. J Thorac Oncol 2008;3:18-22.
27. Eberhard DA, Johnson BE. Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
28. Massarelli E. Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-6.
29. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87.
30. Zhang Y, Banerjee S, Wang Z, et al. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-κB in pancreatic cancer. Cancer Res 2006;66:1025-32.
31. Sunada H, Magun BE, Mendelsohn J, et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci US A1986;83:3825-9.
32. Lenferink AE, Pinkas-Kramarski R, van de Poll ML. et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998; 17:3385-97.